顺铂联合盐酸表柔比星治疗晚期子宫内膜癌的效果及对血清sFLT1、TSGF的影响  

The effect of cisplatin combined with epirubicin on advanced endometrial cancer and the effect on serum sFLT1 and TSGF

作　　者：吴亚岭 WU Ya-ling(Nantong City Cancer Hospital,Pharmaceutical Preparation Section,Nantong 226001,China)

机构地区：[1]南通市肿瘤医院药剂科,江苏南通226001

出　　处：《黑龙江医药科学》2022年第3期56-58,共3页Heilongjiang Medicine and Pharmacy

摘　　要：目的:探讨顺铂联合盐酸表柔比星治疗晚期子宫内膜癌的效果及对血清可溶性血管内皮生长因子受体1(sFLT1)、恶性肿瘤特异性生长因子(TSGF)的影响。方法:选取2017-01~2019-03在我院治疗的晚期子宫内膜癌患者98例,将患者随机分为观察组(n=50)和对照组(n=48),其中观察组给予顺铂联合盐酸表柔比星治疗,对照组该有顺铂治疗,观察两组治疗疗效、不良反应及预后,检测血清sFLT1、TSGF水平。结果:观察组治疗疗效优于对照组(P<0.05),其治疗总有效率为64.00%;观察组治疗后血清sFLT1为(91.10±18.80)pg/mL,明显高于对照组(P<0.05),而TSGF为(42.20±13.32)U/L,明显低于对照组(P<0.05);观察组和对照组不良反应发生率比较差异无统计学意义(P>0.05);观察组中位无进展生存时间和总体生存时间分别为10个月(95%CI:9.32~10.68)和14个月(95%CI:13.51~14.49),明显长于对照组(P<0.05)。结论:顺铂联合盐酸表柔比星治疗晚期子宫内膜癌有较好的效果,降低血清TSGF水平,升高血清sFLT1水平。Objective:To investigate the effect of cisplatin combined with epirubicin on advanced endometrial cancer and the effect on serum soluble vascular endothelial growth factor receptor 1(sFLT1)and tumor specific growth factor(TSGF).Methods:From January 2017 to March 2019,98 patients with advanced endometrial cancer were selected,the patients were randomly divided into observation group(n=50)and control group(n=48),the observation group was treated with cisplatin and epirubicin hydrochloride,while the control group was treated with cisplatin,the therapeutic effect,adverse reactions and prognosis of the two groups were observed,and the serum levels of sFLT1 and TSGF were measured.Results:The therapeutic effect of the observation group was better than that of the control group(P<0.05),and the total effective rate was 64.00%;The serum sFLT1 of the observation group was(91.10±18.80)pg/mL,which was significantly higher than that of the control group(P<0.05),while the TSGF was(42.20±13.32)U/L,which was significantly lower than that of the control group(P<0.05);There was no significant difference in the incidence of adverse reactions between the observation group and the control group(P>0.05);The median progression free survival time and overall survival time of the observation group were 10 months(95%CI:9.32~10.68)and 14 months(95%CI:13.51~14.49),which were significantly longer than those of the control group(P<0.05).Conclusion:Cisplatin combined with epirubicin hydrochloride has a better effect in the treatment of advanced endometrial cancer,can reduce the level of serum TSGF and increase the level of serum sFLT1.

关 键 词：顺铂 盐酸表柔比星 晚期子宫内膜癌 临床效果 可溶性血管内皮生长因子受体1 恶性肿瘤特异性生长因子 

分 类 号：R737.33[医药卫生—肿瘤]